These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 2148245

  • 1. [Response of estrogen and progesterone receptors to treatment with large doses of progestogen (depo-provera) in endometrial cancer].
    Thurzó L.
    Zentralbl Gynakol; 1990; 112(17):1111-5. PubMed ID: 2148245
    [Abstract] [Full Text] [Related]

  • 2. [Estrogen and progesterone receptors in endometrial carcinoma during high-dose progestogen (Depo-Provera) therapy].
    Thurzó L, Sas M, Falkay G.
    Orv Hetil; 1986 Oct 26; 127(43):2613-6. PubMed ID: 2947029
    [No Abstract] [Full Text] [Related]

  • 3. [Surface changes in endometrial cancer under the effect of large doses of progestogen (Depo-Provera)].
    Szarvas Z, Zsolnai B.
    Morphol Igazsagugyi Orv Sz; 1984 Apr 26; 24(2):92-9. PubMed ID: 6717452
    [No Abstract] [Full Text] [Related]

  • 4. Effect of progestogen (Depo-Provera) on annulate lamellae in endometrial carcinoma.
    Szarvas Z, Zsolnai B.
    Acta Chir Hung; 1984 Apr 26; 25(4):269-76. PubMed ID: 6240879
    [Abstract] [Full Text] [Related]

  • 5. Hormone-resistant endometriosis following total abdominal hysterectomy and bilateral salpingo-oophorectomy: correlation with histology and steroid receptor content.
    Metzger DA, Lessey BA, Soper JT, McCarty KS, Haney AF.
    Obstet Gynecol; 1991 Nov 26; 78(5 Pt 2):946-50. PubMed ID: 1833687
    [Abstract] [Full Text] [Related]

  • 6. [Effect of long-term high-dose progesterone (Depo-Provera) therapy on endometrial carcinoma].
    Szarvas Z, Zsolnai B, Gimes G, Hidvégi J.
    Morphol Igazsagugyi Orv Sz; 1985 Oct 26; 25(4):253-60. PubMed ID: 2933583
    [No Abstract] [Full Text] [Related]

  • 7. [Growth of endometrial cancer and hormone].
    Kanoh H, Hosono T, Matsui Y, Okudaira Y.
    Gan To Kagaku Ryoho; 1989 Dec 26; 16(12):3696-703. PubMed ID: 2531993
    [Abstract] [Full Text] [Related]

  • 8. [Progestogen therapy in the treatment of endometrial cancer--clinical results and mechanism of steroid action].
    Okada H.
    Gan To Kagaku Ryoho; 1988 Apr 26; 15(4 Pt 2-1):924-8. PubMed ID: 2968780
    [Abstract] [Full Text] [Related]

  • 9. [Progesterone receptors in endometrial carcinoma and their response to medroxyprogesterone acetate].
    Feng YJ, Zhang XY.
    Zhonghua Fu Chan Ke Za Zhi; 1989 May 26; 24(3):153-5, 189. PubMed ID: 2530067
    [Abstract] [Full Text] [Related]

  • 10. [OEstradiol and progesterone steroid hormone receptors in cancer of the endometrium. The significance of the progesterone receptor (author's transl)].
    Martin PM, Rolland PH, Gammerre M, Serment H.
    J Gynecol Obstet Biol Reprod (Paris); 1979 May 26; 8(8):681-4. PubMed ID: 553927
    [Abstract] [Full Text] [Related]

  • 11. [Cell surface changes after high-dosage progesterone treatment in endometrial carcinoma].
    Szarvas Z, Zsolnai B.
    Zentralbl Gynakol; 1984 May 26; 106(14):1010-7. PubMed ID: 6239468
    [Abstract] [Full Text] [Related]

  • 12. [Therapy of advanced endometrial cancer].
    Okada H, Yamamoto T.
    Gan To Kagaku Ryoho; 1990 Sep 26; 17(9):1848-55. PubMed ID: 2144105
    [Abstract] [Full Text] [Related]

  • 13. Short-term effects of tamoxifen, medroxyprogesterone acetate, and their combination on receptor kinetics and 17 beta-hydroxysteroid dehydrogenase in human endometrium.
    Neumannová M, Kauppila A, Kivinen S, Vihko R.
    Obstet Gynecol; 1985 Nov 26; 66(5):695-700. PubMed ID: 2997680
    [Abstract] [Full Text] [Related]

  • 14. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
    Nola M, Jukić S, Ilić-Forko J, Babić D, Uzarević B, Petrovecki M, Suchanek E, Skrablin S, Dotlić S, Marusić M.
    Gynecol Oncol; 1999 Mar 26; 72(3):331-6. PubMed ID: 10053103
    [Abstract] [Full Text] [Related]

  • 15. Changes in receptor status after treatment with tamoxifen in endometrial cancer.
    Oriana S, Raspagliesi F, Duca PG, Coradini D, Di Re EM, Ragazzi D, Grillo T, Luciani L.
    Int J Biol Markers; 1988 Mar 26; 3(4):233-6. PubMed ID: 3235850
    [Abstract] [Full Text] [Related]

  • 16. Morphology of human uterine cancer in nude mice. Effects of hormone and antihormone treatment.
    Zaino RJ, Satyaswaroop PG, Mortel R.
    Arch Pathol Lab Med; 1984 Jul 26; 108(7):571-8. PubMed ID: 6547322
    [Abstract] [Full Text] [Related]

  • 17. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
    Nomura Y, Tashiro H, Hisamatsu K, Shinozuka K.
    Anticancer Res; 1988 Jul 26; 8(4):647-51. PubMed ID: 2972248
    [Abstract] [Full Text] [Related]

  • 18. Reply to Dr. Edwin B. McDaniel. Exaggerated claims of depo-provera safety.
    Minkin SF.
    Women Health; 1981 Jul 26; 6(1-2):125-9. PubMed ID: 6223451
    [Abstract] [Full Text] [Related]

  • 19. Modalities and results of a combined anti-estrogenic therapy by means of tamoxifen and medroxyprogesterone in gynecologic cancerology.
    Bonte J, Janssens JP, Ide P.
    Eur J Gynaecol Oncol; 1986 Jul 26; 7(1):45-50. PubMed ID: 2938955
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.